Accutar Biotechnology

7 articles about Accutar Biotechnology

• Evommune and Accutar Biotechnology Announce AI Drug Discovery Collaboration

  11/28/2023

  Evommune, Inc. and Accutar Biotechnology Inc. today announced a new strategic partnership focused on the discovery of novel small molecule drug candidates in chronic inflammatory diseases.

• Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study in Patients with Relapsed/Refractory B-cell Malignancies

  6/20/2023

  Accutar Biotechnology, Inc. today announced the dosing of the first patient in a Phase 1 study of AC0676, an orally bioavailable, chimeric degrader molecule designed to target and degrade Bruton's Tyrosine Kinase (BTK) with high potency, selectivity, and broad mutant coverage.

• Accutar Biotechnology Announces First Patient Dosed in China with AC0176 in Phase 1 Study in Prostate Cancer

  2/23/2023

  Accutar Biotechnology, Inc announces the dosing of the first patient in China in a Phase 1 study of AC0176, an orally bioavailable chimeric degrader molecule designed to target Androgen Receptor (AR) protein with high potency and selectivity.

• Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0676 in B-cell Malignancies

  2/3/2023

  Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug application (IND) for AC0676 for the treatment of patients with relapsed/refractory B-cell malignancies.

• Accutar Biotechnology Announces First Patient Dosed in China with AC0682 in Phase 1 Study in ER-Positive Breast Cancer

  10/11/2022

  Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, announces the dosing of the first patient in China in a Phase 1 study of AC0682, an orally bioavailable chimeric degrader molecule designed to target ERα protein with high potency and selectivity.

• Accutar Biotechnology Receives NMPA Clearance of IND Application for AC0176 in Prostate Cancer

  8/19/2022

  Accutar Biotechnology, Inc. , a clinical stage biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, announces that the China National Medical Products Administration (NMPA) has cleared the company’s investigational new drug application (IND) for AC0176 for the treatment of patients with metastatic Castration Resistant Prostate Cancer (mCRPC).

• Accutar Biotechnology Announces Fast Track Designation Granted by FDA to AC0176 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

  6/1/2022

  Accutar Biotechnology, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AC0176 for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) with disease progression on or after treatment with androgen receptor signaling inhibitors